201 results on '"Bittenbring, Joerg"'
Search Results
2. Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas
3. The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
4. Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis
5. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma
6. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
7. Successful treatment of refractory donor‐specific‐human leukocyte antigen‐antibody‐induced primary graft‐failure with daratumumab: A case report.
8. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
9. Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential
10. Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies
11. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity
12. Daratumumab for a Patient With Refractory Antineutrophil Cytoplasmatic Antibody–Associated Vasculitis
13. Integrated meta-omic analyses of the gastrointestinal tract microbiome in patients undergoing allogeneic hematopoietic stem cell transplantation
14. Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
15. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP
16. Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
17. Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma
18. Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
19. IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination
20. Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2
21. Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
22. Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells.
23. Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)
24. Advances in Lymphoma Molecular Diagnostics
25. The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma: A Long Term Pooled Trials Analysis
26. Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients
27. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial
28. Autoantibodies against Progranulin and IL-1 receptor antagonist due to immunogenic posttranslational isoforms contribute to hyperinflammation in critically ill COVID-19
29. Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20+ B-cell lymphomas
30. The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells
31. Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens
32. Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas
33. Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients
34. Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition
35. Fast-Track Schedule for Vitamin D3 Substitution in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
36. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
37. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
38. Review for "CD8+ T cells mediate ultraviolet A‐induced immunomodulation in a model of extracorporeal photochemotherapy"
39. Review of "CD8+ T cells mediate ultraviolet A‐induced immunomodulation in a model of extracorporeal photochemotherapy"
40. FRI0384 IMPACT OF INTERLEUKIN 17 BLOCKING AGENT ON CLINICAL OUTCOME IN SAPHO PATIENTS
41. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
42. MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
43. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
44. Lenalidomide enhances MOR202-dependent macrophage -mediated effector functions via the vitamin D pathway
45. A 71-Year-Old Man With Chest Pain and a Solitary Pulmonary Mass
46. Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide
47. the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity
48. Salvage High-Dose Melphalane and Autologous Peripheral Blood Stem Cell Transplantation for Diffuse Large b-Cell Lymphoma Refractory to 2nd or 3rd Line Treatment
49. Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
50. Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.